Abstract
Background: Results of clinical trials with cardiovascular (CV) and renal outcomes led to a significant change of the treatment guidelines in type 2 diabetes (T2D). Medications with proven cardio-renal benefit (sodium-glucose co-transporter 2 inhibitors, SGLT2i and glucagon-like peptide 1 receptor agonists, GLP-1 RA) are now recommended as first add-on to metformin in subjects with indicators of high-risk (IHR) or established atherosclerotic CV disease (ASCVD), heart failure (HF), and chronic kidney disease (CKD).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
